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ABSTRACT: Synthesis of ligand-functionalized nanomaterials with control
over size, shape, and ligand orientation facilitates the design of targeted
nanomedicines for therapeutic purposes. DNA nanotechnology has emerged
as a powerful tool to rationally construct two- and three-dimensional
nanostructures, enabling site-specific incorporation of protein ligands with
control over stoichiometry and orientation. To efficiently target cell surface
receptors, exploration of the parameters that modulate cellular accessibility
of these nanostructures is essential. In this study, we systematically
investigate tunable design parameters of antibody-functionalized DNA
nanostructures binding to therapeutically relevant receptors, including the
programmed cell death protein 1, the epidermal growth factor receptor, and
the human epidermal growth factor receptor 2. We show that, although the native affinity of antibody-functionalized DNA
nanostructures remains unaltered, the absolute number of bound surface receptors is lower compared to soluble antibodies due to
receptor accessibility by the nanostructure. We explore structural determinants of this phenomenon to improve efficiency, revealing
that receptor binding is mainly governed by nanostructure size and DNA handle location. The obtained results provide key insights
in the ability of ligand-functionalized DNA nanostructures to bind surface receptors and yields design rules for optimal cellular
targeting.
■ INTRODUCTION
In the last decades, nanoscale materials have emerged as a
promising biomedical tool for diagnosis and treatment of
diseases.1−3 Nanomedicines are a class of nanomaterials which
can be constructed from polymeric, inorganic, or organic
particles containing biologically active ligands and are
specifically formulated to induce cellular signaling mediated
by ligand−receptor binding or to deliver therapeutic drugs to
specific cells or tissues.4,5 Incorporation of multiple ligands
onto nanoparticles results in a higher avidity toward target
receptors, as a result of multivalency,6,7 and facilitates local
delivery which increases drug accumulation in the site of
interest, enhancing therapeutic efficiency and reducing off-
target effects. Optimization of the synthesis and formulation of
nanomedicines has revealed several parameters that modulate
targeting efficiency and cellular uptake,8 which include the
orientation,9 mobility,10 and surface density of ligands on the
nanoparticle.11−13 In addition, nanoparticle size, shape, and
aspect ratio also influence their uptake and therapeutic
effectiveness.14−17 For example, rod-shaped nanoparticles
display more efficient cell binding compared to spherical
nanoparticles,18 whereas spherical particles more efficiently
enhance cellular uptake.19 To further unlock the potential of
nanomedicines, it is crucial to control the synthesis of the
nanoscale vehicles and, as such, elucidate critical design
parameters for cellular targeting as a function of vehicle
composition, shape, size, and geometry.
The programmability of DNA origami can be employed to
construct well-defined nanostructures that allow site-specific
immobilization of ligands with unprecedented control over
stoichiometry and orientation.20,21 DNA nanostructures have
been used as delivery vehicles by selectively encapsulating drug
molecules that can be released in a controlled fashion when the
DNA nanostructure binds to specific cell types.22,23 Addition-
ally, these nanostructures can be used to study distance effects
of receptor activation with nanometer precision24−28 and
enhance the cellular uptake of therapeutic drugs29,30 and are
able to modulate drug release kinetics.31,32 More specifically, it
has been shown that compact nanostructures with a low aspect
ratio are the preferred delivery vehicles for internalization33
and that larger DNA origami structures exhibit a higher uptake
efficiency.34 Some of the initial challenges for the use of DNA
nanostructures for biomedical applications have been ad-
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dressed and overcome, including low-scale inefficient produc-
tion, poor structural integrity in physiological fluids, and
degradation by nuclease activity, making DNA origami-based
nanostructures a potential platform for the design of tailored
nanomedicines.35−42
To maximize the potential of DNA nanostructures as a
generic platform for precision medicine, it is essential to
analyze all parameters that influence nanostructure perform-
ance. The DNA origami method enables control over
nanostructure shape, size, or ligand orientation and therefore
allows the systematic investigation of a large subset of
parameters that influence cellular targeting efficiency. While
the parameters that modulate cellular uptake are relatively well
understood, it is currently unclear if DNA nanostructures
interfere with the interaction between ligands and cellular
surface receptors. Although research has shown that incorpo-
ration of a protein ligand onto a DNA nanostructure does not
alter the native affinity of the ligand for the receptor,24,43 the
crowded and irregularly shaped cell surface could interfere with
binding of ligand-functionalized DNA nanostructures to
surface receptors as a result of steric hindrance. This can
lead to ineffective cellular binding of DNA nanostructure-
based nanomedicines and subsequently to decreased down-
stream signaling efficiency and reduced therapeutic effective-
ness.
In this study, we aim to systematically evaluate key
parameters that modulate surface receptor binding of anti-
body-functionalized DNA nanostructures (Figure 1a). As a
model platform, we investigate receptor binding to multiple
cellular surface receptors, including programmed cell death
protein 1 (PD1), epidermal growth factor receptor (EGFR),
and human epidermal growth factor receptor 2 (HER2), using
18-helix bundle DNA nanorods functionalized with a single
antibody.24,43 We employ stoichiometric fluorescent labeling of
antibodies to quantitatively assess cellular accessibility and
show that the DNA nanorod limits the absolute number of
cellular surface receptors that are bound compared to the
corresponding free antibody, although the native affinity of the
antibody remains unaltered. Subsequently, we use the cancer
immunotherapy-related PD1 receptor44 to study individual
determinants that govern receptor accessibility in more detail.
Taking advantage of the spatial addressability of DNA origami,
we provide direct evidence that the DNA handle location, in
contrast to linker length and electrostatic interactions, is a key
parameter for optimal receptor binding. We then design
multiple DNA origami structures and observe a negative
correlation between receptor targeting efficiency and DNA
nanostructure size. To understand the role of cellular
determinants, we demonstrate that receptor accessibility is
also influenced by surface receptor density and the presence of
Figure 1. Targeting cellular surface receptors using antibody-functionalized DNA nanorods. (a) Schematic overview of the determinants that
potentially modulate receptor binding of antibody-functionalized DNA nanostructures, including (i) DNA nanostructure size and shape, (ii)
tunable DNA origami design parameters, (iii) receptor density, and (iv) the presence of other cell surface proteins. (b) Reference-free class
averages obtained from single-particle TEM micrographs and electrophoretic mobility analysis of a self-assembly reaction of the 18-helix bundle
nanorod with- (aPD1-NR) and without (empty-NR) the site-specific incorporation of an anti-programmed cell death protein 1 antibody (aPD1).
Scale bar, 50 nm; labels: S, scaffold. (c) Confocal images and (d) flow cytometric analysis of PD1-overexpressing Chinese hamster ovary K1 (CHO-
K1PD1‑high) cells incubated for 1 h with 20 nM of Alexa-647-labeled (AF647) empty-NR, aPD1-NR, or free aPD1. Scale bar, 5 μm. (e) Flow
cytometric analysis of AF647-labeled aPD1 and aPD1-NR titrated to CHO-K1PD1‑high cells for 1 h. The mean fluorescent intensities, corrected for
AF67 labeling efficiency, were fitted to a noncooperative Hill equation and normalized to the fitted maximum fluorescence intensity of cells stained
with AF647-aPD1 to extract the apparent dissociation constant. Individual data points represent the normalized mean fluorescent intensity (MFI)
of 2000 gated single-cell events (n = 3 technical replicates).
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glycoproteins. Finally, we show that limited cellular accessi-
bility of anti-PD1-functionalized DNA nanorods results in
ineffective blocking of cellular PD1/PDL1 interactions in vitro.
Taken together, our analysis provides key insights on the
parameters that modulate receptor accessibility and can be
used to guide the design of DNA origami nanostructures for
optimal cellular targeting.
■ RESULTS AND DISCUSSION
Targeting Cellular Surface Receptors with Antibody-
Functionalized DNA Nanorods. To investigate the role of
DNA nanostructures in the interaction between ligands and
cellular surface receptors, we constructed an 18-helix bundle
DNA nanorod24,31 (NR, 15 × 150 nm2) functionalized with a
single anti-PD1 antibody. We previously developed a modular
conjugation strategy to site selectively couple ssDNA handles
to the Fc domain of antibodies using a small photo-cross-
linkable protein G adaptor that ensures correct antibody
orientation on the DNA nanostructure.43 In this work, we
employed this method to site specifically conjugate two ssDNA
anti-handles to the Fc region of anti-PD1 antibodies (aPD1)
that hybridizes to two complementary ssDNA handles
protruding from the NR surface (Supplementary Figures 1−
3). Agarose gel electrophoresis confirmed the self-assembly of
NRs and transmission electron microscopy revealed site-
specific incorporation of DNA-aPD1 conjugates on the NR
surface (Figure 1b and Supplementary Figures 4−6). Next, we
used an engineered Chinese hamster ovary (CHO-K1) cell line
stably expressing a high level of PD1 receptors to analyze
receptor binding efficiency of AF647-labeled aPD1-NR and
compare it to AF647-labeled free aPD1. We confirmed that the
structural integrity of NRs was maintained during cellular
labeling, while confocal microscopy analysis revealed that both
aPD1-NR and free aPD1 are localized on the cellular
membrane demonstrating successful binding (Figure 1c and
Supplementary Figure 7). In addition, flow cytometric analysis
of CHO-K1PD1‑high cells showed an increase in mean
fluorescence intensity of individual cells labeled with either
aPD1-NR or free aPD1 (Figure 1d). In both measurements;
however, the absolute fluorescent intensity of CHO-K1PD1‑high
cells incubated with aPD1-NR was approximately 10-fold
lower than cells incubated with free aPD1. Previous research
has shown that when incubated for a longer period of time,
DNA origami nanostructures are readily taken up by cells.33,34
Figure 2. Quantification of DNA nanostructure-cell surface receptor interactions. (a) Schematic of the experimental setup to quantitively assess the
absolute fraction of surface receptors targeted using DNA nanostructures. Twenty nM of antibodies, site-specifically labeled with 2 DNA handles,
was incubated for 30 min with cells expressing target receptors and subsequently labeled with 10 nM of a complementary CY5-labeled imager
strand or a CY5-functionalized DNA nanorod that includes complementary handle-extended staple strands for 30 min. (b) Flow cytometric analysis
of DNA nanostructure receptor targeting in three cell lines (CHO-K1PD1‑high, A431, and SKBR3) expressing the PD1, EGFR, and HER2,
respectively. Antibody-DNA conjugates (anti-PD1, Cetuximab, and Trastuzumab, respectively) were titrated to cells and subsequently labeled with
CY5-functionalized imagers (CY5-IM) or CY5-functionalized nanorods (CY5-NR). The mean fluorescent intensities were fitted to a
noncooperative Hill equation and normalized to the fitted MFI of cells labeled with a CY5-functionalized imager to extract the apparent
dissociation constant. (c) Flow cytometric analysis of aPD1-DNA-labeled CHO-K1PD1‑high cells that were incubated once (first staining) or twice
(second staining) with only CY5-IM (blue), only CY5-NR (red), or a combination of both (green). (d) Receptor accessibility of CY5-NR as a
function of tunable design parameters, including linker length (red), negative charge (green), and DNA handle location (blue). Self-assembly of all
DNA nanostructures, including the K10-PEG5K and spermine coating, was confirmed using electrophoretic mobility analysis (Supplementary
Figures 14, 17, and 19). Individual data points represent the normalized MFI of 2000 gated single-cell events (n = 3 technical replicates).
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Since we only incubated cells over the course of 1 h with DNA
nanostructures, we hypothesized that internalization only had a
minor impact on the observed difference in fluorescent
intensity. To fully exclude the possibility that the difference
in fluorescent intensity is due to enhanced internalization of
free aPD1 compared to origami-tethered aPD1, we treated
aPD1-labeled cells with an acidic solution to remove cell
surface aPD1.45 Subsequently, we measured fluorescent
intensity levels using flow cytometry to determine internalized
fluorescent signals. The relative decrease in fluorescent
intensity levels after acid treatment was similar for CHO-
K1PD1‑high cells treated with free AF647-aPD1 or AF647-labeled
aPD1-NR, demonstrating that aPD1 internalization is not the
primary contributor to the difference in fluorescent intensity
(Supplementary Figure 8). We also tested whether the low
fluorescent signal might be a result of the purification method
used to remove uncoupled aPD1-DNA conjugates from
functionalized aPD1-NR nanostructures. Purification of
aPD1-NRs using agarose gel extraction46 instead of two
rounds of PEG precipitation, however, showed similar
differences in fluorescent intensity between free AF647-aPD1
and AF647-labeled aPD1-NRs, excluding the purification
method as a main source for the low levels of fluorescent
intensity (Supplementary Figure 9). Collectively, these results
indicate that NRs limit PD1 binding.
To assess the impact of NRs on receptor binding affinity, we
titrated AF647-labeled aPD1-NR or free aPD1 against CHO-
K1PD1‑high cells and measured the mean fluorescence intensity
using flow cytometry.43,47 After correcting for AF647 labeling
efficiency (Supplementary Figure 10), CHO-K1PD1‑high labeling
with free aPD1 resulted in an absolute fluorescent intensity 20-
fold higher compared to aPD1-NR labeling (Figure 1e).
Surprisingly, this large difference in fluorescent intensity did
not translate to a different apparent dissociation constant
(KD,app) of free aPD1 and aPD1-NR, indicating that aPD1
retained its affinity when immobilized onto NRs. These
experimental results were rationalized using a thermodynamic
model that describes binding of antibodies to surface-tethered
receptors and is able to explain the observed difference in
fluorescent intensity between free aPD1 and aPD1-NR in
relation to the measured the KD,app (Supplementary Notes and
Supplementary Figure 31). Using the model, we show that
KD,app, in contrast to the absolute fluorescent intensity, is
independent of the absolute number of bound receptor
binding sites and only a function of the fractional occupancy
of cell surface receptors. Experimentally this was verified by
titrating AF647-labeled aPD1 to CHO-K1 cells expressing low,
intermediate, and high levels of PD1, respectively (Supple-
mentary Figure 11). Translating these results to the
experimental data of aPD1-NR binding to CHO-K1PD1‑high
cells (Figure 1e), we therefore hypothesized that steric
hindrance of NRs limits the absolute number of receptors
that can bind to aPD1-NR nanostructures. Taken together, our
results reveal that the native affinity of DNA origami-tethered
aPD1 antibodies remains unaltered compared to free aPD1 but
that the absolute number of bound DNA nanostructures is
lower compared to the free antibody, resulting in a lowered
binding efficiency.
Quantifying Availability of Cellular Surface Receptors
to DNA Nanorods. Having shown that the DNA nanorod
limits receptor binding efficiency of DNA origami-tethered
aPD1 antibodies to CHO-K1PD1‑high, we sought to quantify the
absolute availability of cellular receptors to DNA nanostruc-
tures. We therefore developed a general assay, using a two-step
labeling method, in which we first labeled cells with DNA-
antibody conjugates and subsequently incubated DNA-anti-
body-labeled cells with either a small CY5-functionalized
imager strand (CY5-IM) or a CY5-functionalized DNA
nanorod (CY5-NR) (Figure 2a). Compared to the direct
labeling method used previously to determine KD,app (Figure
1e), this two-step labeling assay excludes the potential
inhibiting effect DNA nanorods can have on antibody-receptor
binding since we ensure that the interaction between the
antibody and the receptor, which takes place in the first step, is
not altered by the DNA nanorod. Consequently, this assay
allows direct quantification of the ability of DNA nanorods to
target antibody-ODN conjugates compared to a smaller imager
probe and determine cellular accessibility more accurately.
DNA-antibody conjugates are site-specifically functionalized
with two ssDNA handles and are therefore either available to
two fluorescently labeled imager strands or a single CY5-NR
(Figure 1b). To establish proof of concept, we titrated DNA-
aPD1 conjugates to CHO-K1PD1‑high and fluorescently labeled
the cells using a fixed concentration of imager or NR and
obtained similar KD,app as previously determined (compare
Figures 1e and 2b and Supplementary Figure 12), while the
absolute fluorescent intensities showed an over 10-fold
difference. Next, we evaluated receptor binding efficiency of
NRs to A431 and SKBR3 cells, expressing therapeutically
relevant EGFR and HER2, respectively. To this end,
therapeutic antibodies Cetuximab (anti-EGFR) and Trastuzu-
mab (anti-HER2) were conjugated to two ssDNA handles and
titrated to A431 and SKBR3 cells, respectively (Supplementary
Figure 13). Both experimental results similarly confirmed that
receptor binding efficiency was decreased when cells were
labeled with NRs, while KD,app remained unaltered (Figure 2b).
To exclude the possibility that the decrease in fluorescent
intensity was a result of DNA-antibody or receptor
dissociation, ssDNA imager internalization or DNA nanorod
impurities (e.g., anti-handle excess still present after NR
purification), we performed two additional control experi-
ments. First, unlabeled CHO-K1PD1‑high cells that were
incubated with CY5-IM or CY5-NR showed similar levels of
fluorescent intensity, confirming that CY5-IM and CY5-NR
internalization did not impact observed differences in
fluorescent intensity (Figure 2c, gray circles). Subsequently,
we simultaneously assessed DNA-antibody/receptor dissocia-
tion and the influence of DNA nanorod impurities by
introducing an additional washing and labeling step. In this
experiment, we incubated DNA-aPD1-labeled CHO-K1PD1‑high
cells once or twice with CY5-IM or CY5-NR. Measuring the
fluorescent intensity after one-step or two-step labeling did not
reveal a decrease in fluorescent intensity for CHO-K1PD1‑high
cells labeled only with CY5-IM or CY5-NR, indicating no
apparent dissociation of the antibody (Figure 2c, blue and red
circles). Simultaneously, incubating DNA-aPD1-labeled CHO-
K1PD1‑high cells first with CY5-NR followed by CY5-IM
displayed a fluorescent intensity similar to cells incubated
with only CY5-IM (Figure 2c, compare blue and green circles),
confirming that CY5-NR binds only a fraction of available
receptor binding sites. Collectively, these results illustrate that
the absolute number of cellular surface receptors targeted by
DNA nanorods is limited and comprises only a small fraction
of all target receptors present on the cellular surface.
Determinants of Cellular Binding Efficiency. The
limited cellular binding efficiency of DNA nanorods
Journal of the American Chemical Society pubs.acs.org/JACS Article
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encouraged us to explore determinants of NR that play an
important role in receptor binding. First, we focused on the
high local concentration of negative charges in the DNA
nanostructure caused by phosphate groups in the DNA
backbone that might induce electrostatic repulsion in
proximity to the negatively charged cell surface. To counteract
the overall negative charge, we coated NRs with a polyethylene
glycol-oligolysine copolymer which contains 10 repeats of
lysines conjugated to a 5 kDa PEG molecule (K10-PEG5K).
This method has been previously employed to prevent
degradation of DNA nanostructures in low-salt conditions
and protection from nucleases.36 Coating NRs with K10-
PEG5K, however, resulted in decreased cell surface accessibility
compared to uncoated NRs (Figure 2d, green circles and
Supplementary Figure 14). We hypothesized that this was a
result of decreased ssDNA handle availability due to the
relatively large PEG molecules on the NR surface. This was
supported by additional control experiments using K10-PEG5K-
coated aPD1-NRs which suffered less from decreased binding
efficiency compared to uncoated structures (Supplementary
Figure 15). Alternatively, we used spermine for NR coating;
however spermine only showed little improvement in NR
receptor binding (Figure 2d, green circles and Supplementary
Figure 14). Since coating of NRs with polyamines could
enhance cellular uptake of NRs, we additionally demonstrated
that NR internalization was not improved after spermine
coating (Supplementary Figure 16). Taken together, these
experiments revealed that counteracting the overall negative
charge had a minor impact on the binding efficiency of DNA
nanorods, excluding electrostatic repulsion as a major
determinant in cellular binding.
Taking advantage of the inherent programmability of DNA
origami, we next assessed the influence of DNA handle length
and handle location. To this end, multiple NRs were self-
assembled using DNA handles that contain a 0, 8, 16 and 32-
nucleotide (nt) single-stranded linker that separates the
antibody from the NR surface (Supplementary Figure 17 and
Table 4). Unsurprisingly, NRs that contained DNA handles
with a 32-nt spacer showed the highest binding efficiency;
however, the increase in cellular binding was only moderate
compared to other linker lengths (Figure 2d, red circles). In
addition, fortification of the 16-nt and 32-nt linker using a
complementary anti-handle or, in contrast, using only a single
DNA handle to improve rotational freedom for aPD1 binding
did not enhance binding efficiency (Figure 2d, red circles and
Supplementary Figure 18). Finally, we constructed four unique
NR configurations in which the position of the ssDNA handles
was varied (Figure 2d, right bottom and Supplementary Table
4). Since DNA handle incorporation efficiency strongly
correlates with the position in the structure,48 DNA handle
incorporation for each configuration was quantified. Using gel
mobility electrophoresis, we found that the handle incorpo-
ration efficiency of configuration 2 was lower compared to
configurations 1 and 4 (Supplementary Figure 19). Rather
than introducing a theoretical compensation factor to take
DNA handle incorporation into account, we decided to design
an additional configuration 3 similar to configuration 2 which
displayed 3 instead of 2 DNA handles to compensate for the
lower handle incorporation efficiency. Despite the lower
incorporation efficiency, configuration 2 as well as config-
uration 3 showed improved cellular binding efficiency
compared to configurations 1 and 4 (Figure 2d, blue circles).
We attribute this improved binding efficiency to the relative
orientation of NRs with respect to the cell membrane and
therefore the accessibility of tethered antibodies to the cell-
bound receptors.34,49 More specifically, configurations 1 and 4
would result in lateral receptor engagement, whereas
configurations 2 and 3 facilitate axial receptor binding.
Additionally, to demonstrate that handle configuration only
modulates absolute cellular accessibility, and, in agreement
with the thermodynamic model does not translate to a change
in KD,app, we titrated DNA-aPD1 conjugates to CHO-K1PD1‑high
and fluorescently labeled the cells either using configuration 1
or configuration 3. We showed that the absolute fluorescent
intensities showed over 4-fold difference, while we obtained a
similar KD,app (Supplementary Figure 20). Collectively, these
results demonstrate that receptor binding efficiency can be
modulated using DNA handle location and strongly correlates
with NR orientation during receptor engagement.
DNA Nanostructure Size and Shape Influence
Cellular Binding Efficiency. Encouraged by the observed
relation between DNA nanorod orientation and cellular
binding efficiency, we constructed multiple DNA nanostruc-
tures to evaluate the effect of shape and size on receptor
binding. Two additional nanostructures, a twist-corrected
rectangular DNA origami rectangle20,50 (Rec, 75 × 100 nm2)
and a tetrahedral DNA nanostructure51 (Tet), respectively,
were successfully folded and purified (Figure 3a and
Supplementary Figures 21 and 22). Additionally, a 50-nt
Figure 3. Effect of DNA nanostructure size and shape on receptor
accessibility. (a) Schematic overview of the dimensions of different
DNA nanostructures and smaller DNA probes used to target cellular
surface receptors (see also Supplementary Figures 21 and 22). (b)
Flow cytometric analysis of aPD1-DNA-labeled CHO-K1PD1‑high cells
first incubated with 20 nM CY5-functionalized DNA nanostructures
or probes for 30 min (single staining, blue) followed by incubation
with 20 nM CY5-functionalized imagers for 30 min (double staining,
red). Individual data points represent the normalized MFI of 2000
gated single-cell events (n = 3 technical replicates).
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double-stranded binding probe (dsP) was self-assembled. The
DNA nanorod and DNA rectangle contained two ssDNA
handles which facilitate binding to a single antibody
(Supplementary Figure 23). In contrast, the DNA tetrahedron
and double-stranded probe employed a single ssDNA handle
which allows binding of two nanostructures to a single
antibody, comparable to an imager strand (Figure 2a).
Consequently, double-stranded binding probes and tetrahe-
drons are therefore labeled with a single CY5 fluorophore,
while DNA rectangles and nanorods contain two CY5 labels.
To accurately compare binding efficiency, CY5 fluorescent
intensity of all nanostructures should be similar and scale
proportionally with the number of dyes incorporated (e.g., the
fluorescent intensity of the double-stranded binding probe or
tetrahedron should be two times smaller than the fluorescent
signal of DNA rectangles or nanorods). Using fluorescent
intensity measurements and a fixed concentration of CY5-
functionalized nanostructures, we demonstrated similar fluo-
rescent intensities for CY5-IM, CY5-dsP, and CY5-Tet as well
as for CY5-Rec and CY5-NR; however, it also revealed a
nonproportional increase (∼3-fold) in fluorescent intensity
when comparing CY5-IM, CY5-dsP, or CY5-Tet to CY5-Rec
and CY5-NR (Supplementary Figure 24). As a result, receptor
binding efficiencies of the DNA rectangles or nanorods could
be slightly overestimated when compared to the single-
stranded imager, double-stranded probe, or tetrahedron.
However, since the observed difference in fluorescent intensity
between the large DNA nanostructures (i.e., CY5-Rec or CY5-
NR) and the small DNA probe is >10-fold, we decided not to
use a correction factor for this overestimation and directly rely
on the fluorescent intensity observed using flow cytometric
analysis. Incubating all DNA nanostructures with aPD1-DNA-
labeled CHO-K1PD1‑high cells revealed a negative correlation
between nanostructure size and receptor binding efficiency.
The binding efficiency of DNA rectangles, comprising a larger
surface area than DNA nanorods, showed the lowest binding
efficiency, indicating that aspect ratio and surface area are
critical determinants of DNA nanostructure binding (Figure
3b, compare blue circles). Recovery of the fluorescent intensity
after incubating labeled cells with CY5-imager strands
confirmed that the decreased fluorescent intensity was a result
of limited DNA nanostructure binding, rather than DNA-
antibody dissociation or DNA handle impurities (Figure 3b,
red circles). These results collectively demonstrate that
nanostructure size negatively impacts cellular binding and
suggest aspect ratio and surface area as potential parameters
that modulate receptor binding efficiency.
Cellular Determinants of DNA Nanostructure Binding
Efficiency. We have demonstrated that DNA nanostructure
size limits cell surface accessibility and that handle location is a
critical parameter to modulate receptor binding; however, all
these determinants are intrinsically related to the DNA
nanostructure. We therefore next investigated how cellular
features, such as surface receptor density or the presence of a
dense glycocalyx, impact receptor targeting efficiency of DNA
nanostructures. First, we assessed the effect of PD1 density on
nanostructure binding. We hypothesized that overexpression of
target receptors could result in a receptor density that exceeds
the theoretical number of DNA nanostructures that can bind
based on surface area. Consequently, receptor binding of an
individual nanostructure could block access to other surface
receptors, limiting overall availability of receptor binding sites.
To study this effect, we analyzed binding of CY5-IM and CY5-
NR to CHO-K1 cells expressing low, intermediate, and high
levels of PD1 (Figure 4a and Supplementary Figures 11 and
12). Unsurprisingly, CHO-K1 cells incubated with CY5-IM
Figure 4. Effect of cellular determinants on DNA nanostructure−receptor interaction. (a) Flow cytometric analysis of CHO-K1PD1‑high cells
expressing different levels of PD1 (High, Hi; Intermediate, Int; Low, Lo). Cells were labeled with aPD1-DNA followed by incubation with CY5-
functionalized imager or CY5-functionalized DNA nanorod. (b) Flow cytometric analysis of CHO-K1PD1‑high cells that were dissociated using an
enzyme-free dissociation buffer or trypsinization or (c) treated with different concentrations of neuraminidase (Neur.) to remove sialic acids.
Cellular labeling was performed as described in (a). Fluorescein isothiocyanate-linked wheat germ agglutinin (FITC-WGA) was used to detect
sialic acid residues. Individual data points represent the normalized MFI of 2000 gated single-cell events (n = 3 technical replicates).
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displayed a decrease in fluorescent intensity as a function of
receptor density (Figure 4a, compare blue circles). Moreover,
the fluorescent intensity of CHO-K1PD1‑low cells labeled with
CY5-IM exceeds that of CHO-K1PD1‑high cells labeled with
CY5-NR. This indicates that even CHO-K1PD1‑low cells express
sufficient PD1 receptors to reach similar fluorescent intensity
levels as CHO-K1PD1‑high cells when incubated with CY5-NR.
Specifically, if overexpression of target receptors significantly
interferes with DNA nanostructure binding, the fluorescent
intensity of CHO-K1PD1‑low labeled with CY5-NR should be
comparable to that of CY5-NR-labeled CHO-K1PD1‑high cells.
Analyzing binding of CY5-NR to CHO-K1 cells, however,
displayed a decreasing trend in fluorescent intensity as a
function of PD1 expression comparable to CY5-IM, providing
direct evidence that PD1 density plays a minor role in DNA
nanostructure binding for the investigated densities (Figure 4a,
compare red circles). In addition to target receptor density, we
also explored whether the presence of other surface proteins
present in the crowded environment of the cell membrane
could interfere with DNA nanostructure binding. To examine
this, we analyzed binding of CY5-IM and CY5-NR to CHO-
K1PD1‑high cells that were dissociated using the proteolytic
enzyme trypsin. Since trypsin treatment also degrades PD1
receptors present on the cell surface, this leads to an overall
decrease of PD1 density which, in combination with the
degradation of other cell surface, should mitigate the effect of
steric hindrance. Treating cells with trypsin resulted in a 6.8-
fold difference in fluorescent intensity between CY5-IM and
CY5-NR compared to a 17.2-fold difference observed for
untreated cells, indicating that a crowded cellular surface limits
DNA nanostructure binding (Figure 4b). Taken together,
these results illustrate that target receptor density in
combination with a crowded cellular surface negatively impacts
receptor accessibility.
Having established that receptor accessibility is sensitive to
the presence of cellular surface proteins, we sought to examine
the impact of the glycocalyx on DNA nanostructure binding.
Previous research has shown that enzymatic digestion of the
glycocalyx resulted in enhanced nanoparticle uptake.52,53 To
assess the effect of the glycocalyx on DNA nanostructure
receptor binding, CHO-K1PD1‑high cells were treated with
neuraminidase to selectively remove sialic acids (Figure 4c).
CHO-K1PD1‑high cells treated with neuraminidase and incu-
bated with CY5-IM did not exhibit improved labeling
efficiency, indicating that the small imager is not affected by
glycocalyx composition. In contrast, cells incubated with CY5-
NR displayed a 2.3-fold increase in fluorescent intensity,
confirming that the glycocalyx interferes with DNA nanostruc-
ture binding. Overall, these findings indicate that receptor
targeting efficiency of DNA nanostructures is not only
dependent on nanostructure design but is also significantly
impacted by cell membrane properties.
aPD1-Functionalized DNA Nanorods Do Not Block
Immune Checkpoint Receptors. Finally, to correlate
cellular binding efficiency and modulation resultant down-
stream signaling, we explored how limited cellular binding
efficiency of DNA nanostructures translates to receptor
blocking efficiency in vitro. As receptor blocking efficiency is
pivotal to effective immunotherapy,44 we hypothesized that
low receptor binding efficiency of aPD1-functionalized nano-
rods could result in a decreased checkpoint blockade and,
additionally, that an optimized antibody configuration on the
DNA nanorod (configuration 3, Figure 2d) could improve
blocking efficiency. For these studies, we used a commercially
available bioassay to measure the ability of aPD1 to block
PD1/PDL1 interactions based on Jurkat TPD1/TCR cells
reporters and CHO-K1PDL1/APC cells as antigen presenting
cells (Figure 5a). When aPD1 antibodies were titrated to a
coculture of Jurkat TPD1/TCR cells and CHO-K1PDL1/APC, Jurkat
TPD1/TCR cells responded in a dose-dependent manner,
indicating inhibitory activity of PD1 signaling in this cell
system (Supplementary Figure 25). Before assessing the
blocking efficiency of aPD1-functionalized nanorods, we
performed additional control experiments to validate the
purity and structural integrity of DNA nanorods in culture
medium. After aPD1-functionalization of DNA nanorods, we
employed two rounds of PEG precipitation43,54 or agarose gel
extraction46 to remove free aPD1 and found that only agarose
gel purification resulted in full removal of free aPD1 antibodies
(Supplementary Figures 26 and 27). Additionally, we
confirmed the stability of aPD1-functionalized nanorods in
culture medium for the duration of the blocking assay
(Supplementary Figure 28). Treating a coculture of Jurkat
TPD1/TCR cells and CHO-K1PDL1/APC with empty-NR, aPD1-
NR1, aPD1-NR3, and free aPD1 revealed that free aPD1
showed a higher blocking PD1/PDL1 blocking efficiency
signaling (Figure 5b). Surprisingly, no significant difference in
receptor blocking efficiency was found between aPD1-NR1 and
aPD1-NR3. Previous research has shown that next to PD1
Figure 5. aPD1-functionalized DNA nanostructures are inefficient
immune checkpoint inhibitors. (a) Schematic of the cell assay to
detect the potency of aPD1-functionalized DNA nanorods (aPD1-
NR) to block PD1/PDL1 interactions. Specifically, artificial antigen-
presenting (aAPC) CHO-K1PDL1/APC cells that express the pro-
grammed death-ligand 1 (PDL1) were cocultured with Jurkat
TPD1/TCR cells stably expressing PD1, T-cell receptors (TCRs), and
a luciferase induced by nuclear factor of activated T cells. (b)
Luciferase expression from a CHO-K1PDL1/APC /Jurkat TPD1/TCR cell
coculture treated with empty-NR, aPD1-NR1, aPD1-NR3, and free
aPD1. One-way analysis of variance was used followed by Tukey’s
multiple-comparison test (***P < 0.001). Individual data points
represent normalized luminescence (Lum.). Experiment was
performed with five technical replicates for each experiment.
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receptor occupation level, the nanoscale spatial organization of
PD1 receptors plays an important role in PD1 inhib-
ition.28,55,56 We therefore hypothesize that the improved
cellular accessibility of aPD1-NR3 on itself is not sufficient to
improve blocking efficiency compared to aPD1-NR1. Never-
theless, these results illustrate that inefficient cellular targeting
of antibody functionalized DNA nanostructures directly
translates to decreased receptor blocking efficiency in vitro.
■ CONCLUSIONS
DNA nanotechnology has facilitated the design of a library of
nanostructures that have been shown to be stable in cellular
environments and can be readily modified with small
molecules or protein ligands to study cellular signaling at the
nanoscale or act as programmable delivery vehicles.57,58 Here,
we evaluated the receptor binding efficiency of antibody-
functionalized DNA nanostructures to elucidate critical design
parameters that can promote or hamper cellular binding. Our
results reveal that, while the native affinity of incorporated
antibodies remains unaltered, the absolute number of surface
receptors targeted by antibody-functionalized DNA nanostruc-
tures is reduced when compared to free antibodies. Systematic
evaluation of nanostructure design parameters revealed that
nanostructure orientation and size are key parameters for
efficient receptor binding and demonstrated that the cell
surface composition acts as a natural barrier that limits
receptor accessibility. Based on these findings, we hypothesize
that steric hindrance caused by the larger DNA nanostructures
is the primary contributor to limited receptor binding
efficiency. A potential application of this nanostructure
induced steric hindrance could comprise the formation of a
steric barrier around the cell that is able to block all ligand−
receptor interactions. However, experimental evidence showed
that the binding of large DNA nanostructures to surface
receptors did not prevent other, smaller, probes from accessing
unbound receptors, excluding the possibility of using large
DNA nanostructures as tools for cell signaling blockage.
Moreover, a cellular assay that assessed the immune
checkpoint blockade displayed that decreased receptor binding
efficiency of aPD1 nanostructures directly translated to limited
blocking of immune checkpoint receptors. This result
highlights important considerations for the use of nanostruc-
tures in biological systems and their therapeutic effectiveness.
For example, smaller nanostructures containing only a limited
number of therapeutic antibodies might be beneficial over
larger nanostructures that contain multiple antibodies to block
ligand−receptor signaling. Rationalizing the impact of
individual design parameters for ligand-functionalized DNA
nanostructures therefore provides a powerful addition to the
design criteria for nanostructures targeting cellular surface
receptors.
Aside from the absolute number of receptors that are
targeted, cellular activation mechanisms also play a major role
in cellular signaling. Previous work, which employed DNA
nanostructures to study distance-dependent effects of receptor
activation with nanometer precision, showed that ligand-
functionalized DNA origami structures induced a similar or
even enhanced cellular signaling compared to soluble
ligands.24,26,28,59 Combining these results with the findings in
our work suggests that the number of bound ligand-
functionalized DNA nanostructures compared to soluble
ligands is not the only determinant that could modulate
cellular signaling. Moreover, the combination of multiple
ligands at the same nanoparticles has shown in the past to be
advantageous to enhance selectivity by either bispecific or
multivalent interactions.47,60 Since DNA nanostructures can be
programmed as drug delivery systems to display or encapsulate
therapeutic molecules that are released upon binding to
specific surface proteins22,23 the results in this work provide the
scientific community with guidelines to display targeting
ligands at locations that are easily accessed by the cell, while
at the same time incorporating therapeutic functionalities with
potential side effects at locations with limited cellular
accessibility.
At the same time, the role the receptor activation
mechanism plays in cellular signaling underlines the limitations
of using a single parameter, the equilibrium dissociation
constant (KD), to assess ligand-functionalized nanostructure
performance.61 Dissociation constants only refer to the
strength of individual ligand−receptor interactions, excluding
the effect of nanostructure design or cellular determinants. Our
work shows that the efficacy of cellular targeting is dictated by
a combination of receptor affinity and accessibility of receptors
at the target site. As such, a broader subset of parameters,
which include cell signaling modulation and receptor binding
efficiency, should be explored to maximize the potential of
nanomedicines. We envision that programmable DNA
nanostructures find great application in the elucidation on
critical design parameters that will eventually guide the design
of precision medicines, either composed of nucleic acids,
polymers, or organic molecules.
■ MATERIALS AND METHODS
Materials. Staple strands, handle-extended staple strands, modified
DNA oligonucleotides, and fluorescently modified DNA oligonucleo-
tides were obtained from Integrated DNA Technologies. The p7560
scaffold for the nanorod and M13mp18 scaffold for the rectangle were
obtained from Eurofins. Monoclonal antibodies anti-PD1 (kindly
provided by Aduro Biotech, hPD1.27.C4, batch: 18-FJ8381),
Cetuximab (Erbitux, Merck), and Trastuzumab (Herceptin, Roche)
were used for cell labeling.
Recombinant Protein Expression and Purification. Protein G
was expressed as described previously.62 Briefly, BL21(DE3) cells
(Novagen), transformed with pet28a-protein G and pEVOL-pBpf
(kind provided by Peter Schultz), were grown for 18 h at 25 °C to
express protein G. After lysing the cells using BugBuster (5 mL/g
pellet, Merck) supplemented with benzonase (5 μL/g pellet, Merck),
protein G was purified by Ni-NTA affinity chromatography followed
by Strep-tactin chromatography, and the purity was assessed using
SDS-PAGE gel analysis.
Preparation of Reaction pG-ODNs. ODN coupling was
performed as previously described.62 In a typical reaction, to a
solution of 10 nmol ODN in water (10 μL) were added 1× PBS, pH
7.2 (30 μL) and 100 nmol Sulfo-SMCC (Thermo scientific) in
DMSO (40 μL). The reaction was incubated at 850 rpm for 2 h at 20
°C. Excess Sulfo-SMCC was removed using two rounds of ethanol
precipitation. SMCC-labeled ODNS were precipitated by the addition
of 10% (v/v) 5 M NaCl and 300% (v/v) ice-cold EtOH and
incubating for 75 min at −30 °C. The reaction mixture was
centrifuged at 19,000×g for 30 min at 4 °C, the pellet was
reconstituted in 1× PBS (pH 7.2), and the precipitation was
repeated. After centrifugation, the pellet was washed in 95% (v/v, in
water) ice-cold EtOH, centrifuged at 19,000×g for 15 min and
lyophilized.
For conjugation of pG, to a SMCC-functionalized ODN, an aliquot
of pG was buffer exchanged to (100 mM Sodium Phosphate, 25 μM
TCEP, pH 7) using a PD10 desalting column (GE Healthcare).
Subsequently, desalted pG was concentrated to a final concentration
of 50 μM using Amicon 3 kDa MWCO centrifugal filters (Merck
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Millipore). Ten nmol lyophilized SMCC-functionalized ODN was
reconstituted in 40 μL 50 μM pG (2 nmol) resulting in a 5× excess of
maleimide-ODN. The reaction was shaken at 850 rpm for 3 h at 20
°C.
General Procedure for pG-ODN Antibody Labeling and
Purification. Protein G-ODN conjugates were coupled to an
antibody as described previously.62 Before conjugation of the
antibody to the pG-ODN, all antibodies are buffer exchanged to 1×
PBS (pH 7.4) using Amicon 10 kDa MWCO centrifugal filters
(Merck Millipore). In a typical reaction, a 100 μL aliquot of 4 μM
antibody is mixed with 40 μM of pG-ODN and exposed for 1 h to UV
light (λ = 365 nm) at 4 °C. Coupled antibodies were purified using
size exclusion chromatography on a Agilent 1260 Infinity system
equipped with an Agilent SEC-5, 300A, 7.8 × 300 mm HPLC column.
The flow rate was set to 1 mL/min using 1× PBS, pH 7.2 as a running
buffer. The collected elution fractions were pooled and concentrated
using a 50 kDa MWCO cutoff filter (Merck Millipore). The
concentration of purified antibody−DNA conjugates was determined
with gel band intensity analysis on reducing SDS-PAGE. To this end,
conjugate gel band intensity of the light chain was determined using
the ImageJ (v.1.52n) gel analysis plugin and then compared to a
calibration curve of known concentrations of antibody.
Production of p7560 Scaffold for DNA Nanorod Design. The
7560 nt single-stranded scaffold strand was produced as described in
literature.21,63 In short, 1 μL of 100 nM ssDNA was transformed in 90
μL XL10-Gold Ultracompetent cells (Agilent) and grown overnight at
37 °C on agar plates supplemented with tetracycline (10 μg/mL,
Sigma-Aldrich) according to the manufacturer’s protocol. A plaque
was used to inoculate 300 mL of 2xYT medium (16 g/L peptone, 5 g/
L NaCl, 10 g/L yeast extract) supplemented with 5 mM MgCl2, and
the culture was incubated for 4 h at 37 °C. The cells were pelleted by
centrifugation, and the bacteriophages were extracted from the
supernatant by PEG fractionation.63 After centrifugation, the pellet
was reconstituted in TE buffer (10 mM Tris, 1 mM EDTA, pH 8.5)
and lysed using buffers P2 and P3 (Qiagen). After ethanol
precipitation, the single-stranded phage DNA was reconstituted in
TE buffer and stored at −30 °C in DNA LoBind tubes (Eppendorf).
The concentration was determined by measuring the absorption at
260 nm (ND-1000, Thermo Scientific) and the respective extinction
coefficient (ssDNA 7560: 7.43 × 10−1 cm−1).
Production and Purification of DNA Nanostructures. DNA
Nanorod.24 To self-assemble the 18-helix bundle nanorod 20 nM
ssDNA scaffold (p7560) was mixed with 100 nM of each staple, 12
mM MgCl2, 25 mM NaCl, 5 mM Tris pH 8.5, and 1 mM EDTA.
Folding was carried out by rapid heat denaturation followed by slow
cooling from 80 to 60 °C over the course of 20 min and a subsequent
decrease from 60 to 24 °C for 14 h.
DNA Rectangle.20,50 Folding reactions were performed in 10 mM
Tris, 1 mM EDTA, 10 mM MgCl2, 50 mM NaCl, pH 8.0 with 25 nM
scaffold strand (M13mp18) and 250 nM of each staple strand. The
reaction mixture was heated to 95 °C for 15 min and then slowly
cooled to 20 °C at a rate of 1 °C/min.
Both DNA nanostructures were purified by two rounds of PEG
precipitation54 and finally dissolved in 1× PBS, pH 7.4 and 10 mM
MgCl2. The DNA origami concentration was determined by
measuring the absorption at 260 nm and the respective extinction
coefficients (DNA nanorod: 1.22 × 108 M−1 cm−1, DNA rectangle:
1.24 × 108 M−1 cm−1).
Tetrahedron51 and Double-Stranded DNA Probe. Folding
reactions were performed in 10 mM Tris, 1 mM EDTA, and 5 mM
MgCl2 with 1 μM of each core staple strand and 2 μM of a CY5-
functionalized antihandle. The reaction mixture was heated to 95 °C
for 2 min and then slowly cooled to 20 °C at a rate of 1 °C/90 s.
Assembled nanostructures were analyzed and subsequently purified
using native polyacrylamide gel electrophoresis (PAGE) extraction
and dissolved in 5 mM Tris (pH 8.0), 0.5 mM EDTA, and 5 mM
MgCl2 for long-term storage or 1× PBS, pH 7.4 and 10 mM MgCl2
for immediate use. The concentration was determined by measuring
the absorption at 260 nm and the respective extinction coefficients
(DNA tetrahedron: 2.66 × 106 M−1 cm−1, DNA double-stranded
probe: 1.06 × 106 M−1 cm−1).
Antibody-Nanorod Production and Purification. Incorpora-
tion of DNA-labeled antibodies onto purified DNA origami
nanostructures was performed by incubating DNA origami with 4
mol equiv of antibody-DNA for 1 h at 37 °C, followed by 2h at 22 °C
in 1× PBS, pH 7.4 and 10 mM MgCl2. Removal of excess antibody-
DNA was carried out either using two rounds of PEG precipitation as
described before43 (Figure 1) or using 1.5% agarose gel extraction64
(Figure 5). Antibody incorporation efficiency was quantified using
1.5% agarose gel electrophoresis in combination with gel band
intensity analysis performed using ImageJ (NIH).
Transmission Electron Microscopy. The 2.5 nM DNA
nanorods were adsorbed for 1 min onto grids (Cressington
206Carbon) that were surface plasma treated for 40 s. Subsequently,
the grids were stained with a 0.4% (w/v) aqueous uranyl acetate
solution, and excess sample was immediately removed with filter
paper. Imaging was performed at 25,000× and 29,000× magnification
with a Tecnai 200 kV D2029 Twin microscope using transmission
electron microscopy (TEM) uP SA Zoom mode, and images were
captured at 4096 × 4096 pixels with 4.27 Å/pixel and 3.59 Å/pixel,
respectively. The nanoparticles were individually picked (∼20 per
nanostructure) from micrographs with the boxer function in
EMAN2.3.65 Two-dimensional class averages were constructed with
the bispectrum-based class averaging function from EMAN2.3 and
classified into two classes based on mean intensity.
Fluorescent Antibody Labeling. Antibodies were buffer
exchanged to 100 mM sodium phosphate buffer (pH 7.0) using
Zeba spin desalting columns, 7K MWCO (Thermofisher). Alexa-
fluor647 (AF647) NHS ester (Thermofisher) was added in a 20-fold
molar excess and reacted for 2 h at room temperature. Subsequently,
nonreacted dye was removed using Zeba spin desalting columns, 7K
MWCO. The labeling efficiency was based on the absorbance at 280
and 647 nm and assuming extinction coefficients of 210,000 M−1
cm−1 and 270,000 M−1 cm−1 for the antibody and AF647,
respectively. In addition, the contamination of free dye was quantified
using SDS-PAGE gel analysis.
Cell Culture. Monoclonal CHO-K1 cells stably expressing low,
intermediate, and high levels of PD1 (kindly provided by Aduro
Biotech) were cultured in a 75 cm2 flask in Dulbecco’s modified
Eagle/F12 (DMEM/F12) medium (cat: 11320033) supplemented
with 5% fetal bovine serum (FBS) (cat: 26140079), 1% penicillin-
steptomycin (P/S) (cat: 15140122), and 0.8 mg/mL geneticin sulfate
(G418) (cat: sc-29065A). A431 cells (ATCC, cat. no. CRL-1555)
and SKBR3 cells (ATCC, cat. no. HTB-30) overexpressing EGFR and
HER2, respectively, were cultured in RPMI1640 medium (cat:
11875093) supplemented with 10% FBS and 1% P/S. For the SKBR3
cells, the culture medium was supplemented with 1 mM sodium
pyruvate (cat. 11360070). Cells were incubated at 37 °C with 5%
CO2.
Fluorescent Cellular Labeling. Unless stated otherwise, CHO-
K1 cells were harvested using enzyme-free cell dissociation buffer
(cat: 13151014) and A431/SKBR3 cells using trypsin/EDTA
(0.05%) (cat: 25300062). Cells were washed in labeling buffer (1×
PBS, 0.1% BSA (w/v), pH 7.4) and diluted to a final concentration of
3.5 × 106 cells/mL in labeling buffer.
One-step Labeling Using anti-PD1-Functionalized DNA Nano-
rod (Figure 1). 2.86 μL of the cell suspension (10,000 cells) was
incubated in a final volume of 20 μL of labeling buffer containing 20
nM aPD1-Nanorod-AF647 or 20 nM aPD1-AF647. The reaction
mixture was shaken at 400 rpm for 60 min at room temperature.
Subsequently, the labeled cells were centrifuged for 5 min at 1500×g,
and the supernatant was removed. Directly prior to flow cytometry or
confocal microscopy cells were resuspended in 200 μL of labeling
buffer.
Two-Step Labeling Using DNA-Functionalized Antibodies
(Figures 2−4). 4.29 μL of the cell suspension (15,000 cells) was
incubated in a final volume of 30 μL of labeling buffer containing 20
nM DNA-antibody conjugate. The reaction mixture was shaken at
400 rpm for 30 min at room temperature. Subsequently, the labeled
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cells were centrifuged for 5 min at 1500×g, and the supernatant was
removed. The pelleted cells were redissolved in 30 μL of labeling
buffer containing 10 nM complementary CY5-labeled imager strands
or CY5-functionalized DNA nanorods that include a complementary
handle-extended staple strand and incubated at 400 rpm for 30 min at
room temperature. The labeled cells were centrifuged for 5 min at
1500×g, and the supernatant was removed. Directly prior to flow
cytometry, cells were resuspended in 200 μL of labeling buffer.
Confocal microscopy was performed on a Zeiss LSM510 META
NLO equipped with a C-Apochromat 63×/1.2W objective using a
633 nm He/Ne laser. The pinhole was set to 1 airy unit, and images of
2048 × 2048 pixels were acquired with a pixel dwell of 3.2 μs. Flow
cytometry was performed on a FACS Aria III (BD Biosciences)
equipped with a 70 μm nozzle. Events representing single cells were
gated based on the forward height scatter vs the forward area scatter.
For each measurement, fluorescence intensities of 2000 individual
cells were recorded and analyzed using custom-written MATLAB
scripts.
Spermine and K10-PEG5K Coating. Spermine and K10-PEG5K
were dissolved in Milli-Q at a final concentration of 10 mM and 1
mM, respectively. Subsequently, DNA nanostructure coating was
performed for 30 min at 20 °C using N:P ratios of 10 (spermine) or
2.5 (K10-PEG5K), respectively.
Neuraminidase Treatment Cells. Neuraminidase from Clostri-
dium perf ringens (Sigma) was dissolved in 1× PBS, pH 7.4 at a final
concentration of 10 U/mL. For neuraminidase treatment CHO-
K1PD1‑high cells were harvested using enzyme free cell dissociation
buffer and were resuspended in DMEM/F12 medium without FBS,
P/S and G418. Neuraminidase treatment was performed in a total
volume of 150 μL with a cell concentration of 1 × 106 cells for 1h at
37 °C. After incubation cells were centrifuged for 3 min at 1500×g
and washed 1 time in labeling buffer. Subsequently, cells were labeled
using FITC-labeled lectin from Triticum vulgaris (Sigma) at a
concentration of 100 μg/mL for 30 min at 20 °C. The labeled cells
were centrifuged for 5 min at 1500×g, and the supernatant was
removed. Directly prior to flow cytometry or confocal microscopy,
cells were resuspended in 200 μL of labeling buffer.
PD1/PD-L1 Blocking Assay. The PD1/PD-L1 blocking assay
was obtained from Promega (J1255) and was performed according to
the manufacturer’s instructions. Briefly, a sterile 384-well plate
(Thermo Scientific, cat. 164610) was seeded with 25 μL of diluted
PD-L1 aAPC/CHO-K1 thaw-and-use cells (500,000 cells/mL) and
incubated at 37 °C with 5% CO2 for 18 h. After incubation, the 384-
well plate was inverted to remove the culture medium, and cells were
directly incubated with 10 μL of 20 nM IgG, empty-NR, aPD-NR, or
aPD1 in RPMI1640 supplemented with 1% FBS. Subsequently, 10 μL
of diluted PD1 Jurkat T effector thaw-and-use cells (900,000 cells/
mL) was added to the same well to yield a final concentration of 10
nM IgG, empty-NR, aPD-NR, or aPD1. Cells were incubated at 37 °C
with 5% CO2 for 6 h, and luciferase expression was quantified by
adding 20 μL of Bio-Glo reagent. Luminescence was measured in a
Tecan Spark 10 M platereader.
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